Strategy Asset Managers
PPH icon

Strategy Asset Managers’s VanEck Pharmaceutical ETF PPH Stock Holding History

Strategy Asset Managers’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$266K Hold
2,433
– – 0.04% 227
2026
Q2 		$266K Buy
2,433
+492
+25% +$50.9K 0.04% 238
2026
Q1 		$202K Hold
1,941
– – 0.03% 261
2025
Q4 		$200K Buy
+1,941
New +$189K 0.03% 251

Other funds holding PPH

AWC
Adamsbrown Wealth Consultants Wichita, Kansas $548M AUM 16.52% 1-Year Est. Return
Old National Bancorp
Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return
RBC
Rye Brook Capital Greenwich, Connecticut $154M AUM 17.54% 1-Year Est. Return
WWM
WT Wealth Management Scottsdale, Arizona $357M AUM 15.82% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
FF
Fluent Financial Dallas, Texas $292M AUM 8.92% 1-Year Est. Return
Avior Wealth Management
Avior Wealth Management Omaha, Nebraska $3.79B AUM 15.36% 1-Year Est. Return
AWMT
AAFMAA Wealth Management & Trust Fayetteville, North Carolina $291M AUM 14.48% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.52% 1-Year Est. Return
Hudock Inc
Hudock Inc Williamsport, Pennsylvania $790M AUM 18.43% 1-Year Est. Return

Strategy Asset Managers's PPH Position: Q3 2026 in Review

Strategy Asset Managers held its VanEck Pharmaceutical ETF (PPH) position steady in Q3 2026 at 2,433 shares worth $266K. The position accounts for 0.04% of the portfolio, ranked #227.

Strategy Asset Managers first reported a position in PPH in Q4 2025 and has held it in 4 quarters since. 25 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • Strategy Asset Managers held 2,433 shares of VanEck Pharmaceutical ETF worth $266K as of Q3 2026.
  • Strategy Asset Managers left its VanEck Pharmaceutical ETF share count unchanged in Q3 2026.
  • VanEck Pharmaceutical ETF made up 0.04% of Strategy Asset Managers's portfolio in Q3 2026, its #227 holding.
  • Strategy Asset Managers first reported a position in VanEck Pharmaceutical ETF in Q4 2025 and has held it in 4 quarters since.
  • 25 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Strategy Asset Managers's 13F filing for Q3 2026, filed 14 Oct 2026.